Agriculture company Calyxt Inc (NASDAQ: CLXT) announced on Thursday that it plans to crush and produce its high oleic soybean variety through an agreement with American Natural Processors (ANP), a leading provider of innovative non-GMO and organic processing of oils, flours and meals in Cherokee, Iowa.
ANP will crush Calyxt's high-oleic soybean variety and produce its first high oleic consumer soybean oil, which is expected to hit the market in late 2018 / early 2019.
In conjunction, the high-oleic / low-saturated fat oil from Calyxt's new variety of soybeans is designed to eliminate the need for hydrogenation, a process that improves heat stability and shelf life of conventional soybean oil. The process of hydrogenation for conventional soybean oil contributes to the production of trans-fatty acids, which, when consumed, raises low-density lipoprotein, or LDL, and cholesterol levels, as well as contributes to cardiovascular diseases.
Additionally, Calyxt has received a letter from the USDA confirming that its high-oleic soybean variety is non-regulated, as the product contains no foreign DNA.
The US FDA has declared trans fats not generally recognised as safe (GRAS) and human food must no longer contain partially hydrogenated oils by 18 June 2018. The World Health recently unveiled a plan to remove all trans fats worldwide from the food chain by 2023.
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Revier Therapeutics closes EUR6m seed financing and launches operations
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Lundbeck's asedebart
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
PTC to acquire BLA-stage ST-920 Fabry disease programme
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
Mezzion Pharma Co reports positive results from new in vivo study of udenafil
Incyte's Opzelura approved in European Union for moderate atopic dermatitis